Ascentage Pharma Group International’s (AAPG) Buy Rating Reaffirmed at BTIG Research

Ascentage Pharma Group International (NASDAQ:AAPG)‘s stock had its “buy” rating restated by stock analysts at BTIG Research in a research note issued to investors on Friday,Benzinga reports. They presently have a $48.00 price objective on the stock. BTIG Research’s target price points to a potential upside of 177.14% from the stock’s previous close.

AAPG has been the subject of several other reports. Deutsche Bank Aktiengesellschaft started coverage on shares of Ascentage Pharma Group International in a research report on Friday, April 24th. They set a “buy” rating and a $40.00 target price for the company. B. Riley Financial started coverage on Ascentage Pharma Group International in a research report on Wednesday, June 10th. They set a “buy” rating and a $45.00 target price on the stock. Finally, Raymond James Financial reissued a “buy” rating on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. Two research analysts have rated the stock with a Strong Buy rating and eight have given a Buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $46.43.

Ascentage Pharma Group International Price Performance

Ascentage Pharma Group International stock opened at $17.32 on Friday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.77 and a current ratio of 1.79. Ascentage Pharma Group International has a 52-week low of $16.36 and a 52-week high of $48.45. The stock’s 50 day moving average price is $18.21 and its two-hundred day moving average price is $21.23.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its quarterly earnings data on Wednesday, August 19th. The company reported ($0.65) earnings per share (EPS) for the quarter. The firm had revenue of $22.24 million for the quarter. As a group, equities analysts forecast that Ascentage Pharma Group International will post -1.78 EPS for the current year.

Institutional Investors Weigh In On Ascentage Pharma Group International

Several institutional investors have recently modified their holdings of AAPG. UBS Group AG boosted its holdings in shares of Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after buying an additional 10,988 shares during the last quarter. Hsbc Holdings PLC bought a new stake in shares of Ascentage Pharma Group International in the second quarter worth about $391,000. Finally, Citadel Advisors LLC purchased a new position in Ascentage Pharma Group International during the 3rd quarter valued at approximately $383,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.